Table 2.

Summary of results of recent series on stereotactic radiosurgery for GH-secreting pituitary adenomas

Authors	patients	type of	total dose	follow-up	tumor	biochemical remission	late toxicity (%)
		SRS	(Gy)	median (months)	control (%)	(%)	visual	hypopituitarism
Attanasio et al., 2003 [34]	30	GK SRS	20	46	100	30 at 5 years	0	6.7
Jane et al., 2003 [35]	64	GK SRS	15	> 18	NA	36	0	28
Castinetti et al., 2005 [36]	82	GK SRS	26	49.5*	NA	17	1.2	17
Gutt et al., 2005 [37]	44	GK SRS	23	22	100	48	NA	NA
Kobayashi et al., 2005 [38]	67	GK SRS	18,9	63	100	17	11	15
Jezkova et al., 2006 [39]	96	GK SRS	32	53.7	100	44 at 5 years	0	27.1
Voges et al., 2006 [40]	64	LINAC SRS	16,5	54.3	97	14 and 33 at 3 and 5 years	1.4	13 and 18 at 3 and 5 years
Petit et al., 2007 [32]	22	PSRS	20 GyE	75.6	100	59	0	38
Pollock et al., 2007 [41]	46	GK SRS	20	63	100	11 and 60 at 2 and 5 years	0	33 at 5 years
Vik-Mo et al., 2007 [42]	53	GK SRS	26.5	67	100	58 and 86 at 5 and 10 years	3.8	10 at 5 years
Jagannathan et al., 2008 [43]	95	GK SRS	22	57	98	53	4	34
Losa et al., 2008 [44]	83	GK SRS	21,5	69	97	52 and 85 at 5 and 10 years	0	10 at 10 years
Ronchi et al., 2009 [45]	35	GK SRS	20	114	100	46 at 10 years	0	50
Wan et al., 2009 [46]	103	GK SRS	21,4	67	95	37	0	6
Hayashi et al., 2010 [47]	25	GK SRS	25.2	36	100	40	0	0
Iwai et al., 2010 [48]	26	GK SRS	20	84	96	17 and 47 at 5 and 10 years	0	8

*mean follow-up; NA not assessed.

SRS, stereotactic radiosurgery; GKS, Gamma Knife radiosurgery.

PSRS; proton stereotactic radiosurgery.